Methotrexate decreases PP2A methylation and increases tau phosphorylation in neuron

Biochemical and Biophysical Research Communications

Volumn 363, Issue 3, 2007, Pages 811-816

  Yoon, Seung Yong ^a,b   Choi, Hyo In ^a   Choi, Jung Eun ^a   Sul, Chang Ahn ^a   Choi, Jin Myoung ^a   Kim, Dong Hou ^a  

^a University of Ulsan College of Medicine   (South Korea)

^b National Institute of Scientific Investigation   (South Korea)

Author keywords

Alzheimer's disease; APP; BACE; Methyltransferase; Okadaic acid; PP2A; Secretase; Tau

Indexed keywords

AMYLOID PRECURSOR PROTEIN; BETA SECRETASE; FOLIC ACID ANTAGONIST; METHOTREXATE; PHOSPHOPROTEIN PHOSPHATASE 2A; TAU PROTEIN;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL CELL CULTURE; ARTICLE; BRAIN NERVE CELL; CELL ASSAY; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFECT; ENZYME INACTIVATION; FOLIC ACID DEFICIENCY; IMMUNOCYTOCHEMISTRY; MOLECULAR DYNAMICS; NERVE CELL CULTURE; NEUROPATHOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN METHYLATION; PROTEIN PHOSPHORYLATION; RAT; WESTERN BLOTTING;

AMYLOID BETA-PROTEIN PRECURSOR; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; BLOTTING, WESTERN; CELLS, CULTURED; IMMUNOHISTOCHEMISTRY; METHOTREXATE; METHYLATION; NEURONS; PHOSPHORYLATION; PROTEIN PHOSPHATASE 2; RATS; TAU PROTEINS; TIME FACTORS;

RATTUS;

EID: 34848871269     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2007.09.060     Document Type: Article

References (34)

1. Swain R.A., and St Clair L. The role of folic acid in deficiency states and prevention of disease. J. Fam. Pract. 44 (1997) 138-144
2. Elkind M.S., and Sacco R.L. Stroke risk factors and stroke prevention. Semin. Neurol. 18 (1998) 429-440
3. Duthie S.J. Folic acid deficiency and cancer: mechanisms of DNA instability. Br. Med. Bull. 55 (1999) 578-592
4. Allen R.H., Stabler S.P., and Lindenbaum J. Relevance of vitamins, homocysteine and other metabolites in neuropsychiatric disorders. Eur. J. Pediatr. 157 Suppl. 2 (1998) S122-S126
5. Clarke R., Smith A.D., Jobst K.A., Refsum H., Sutton L., and Ueland P.M. Folate, vitamin B12, and serum total homocysteine levels in confirmed Alzheimer disease. Arch. Neurol. 55 (1998) 1449-1455
6. Gray G.E. Nutrition and dementia. J. Am. Diet. Assoc. 89 (1989) 1795-1802
7. Hassing L., Wahlin A., Winblad B., and Backman L. Further evidence on the effects of vitamin B12 and folate levels on episodic memory functioning: a population-based study of healthy very old adults. Biol. Psychiatry 45 (1999) 1472-1480
8. Nilsson K., Gustafson L., Faldt R., Andersson A., and Hultberg B. Plasma homocysteine in relation to serum cobalamin and blood folate in a psychogeriatric population. Eur. J. Clin. Invest. 24 (1994) 600-606
9. Nilsson-Ehle H. Age-related changes in cobalamin (vitamin B12) handling. Implications for therapy. Drugs Aging 12 (1998) 277-292
10. Renvall M.J., Spindler A.A., Ramsdell J.W., and Paskvan M. Nutritional status of free-living Alzheimer's patients. Am. J. Med. Sci. 298 (1989) 20-27
11. Wang H.X., Wahlin A., Basun H., Fastbom J., Winblad B., and Fratiglioni L. Vitamin B(12) and folate in relation to the development of Alzheimer's disease. Neurology 56 (2001) 1188-1194
12. Seshadri S., Beiser A., Selhub J., Jacques P.F., Rosenberg I.H., D'Agostino R.B., Wilson P.W., and Wolf P.A. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N. Engl. J. Med. 346 (2002) 476-483
13. Beyer K., Lao J.I., Latorre P., Riutort N., Matute B., Fernandez-Figueras M.T., Mate J.L., and Ariza A. Methionine synthase polymorphism is a risk factor for Alzheimer disease. Neuroreport 14 (2003) 1391-1394
14. Bottiglieri T., and Hyland K. S-Adenosylmethionine levels in psychiatric and neurological disorders: a review. Acta Neurol. Scand. Suppl. 154 (1994) 19-26
15. Mizrahi E.H., Jacobsen D.W., Debanne S.M., Traore F., Lerner A.J., Friedland R.P., and Petot G.J. Plasma total homocysteine levels, dietary vitamin B6 and folate intake in AD and healthy aging. J. Nutr. Health Aging 7 (2003) 160-165
16. Morris M.S. Homocysteine and Alzheimer's disease. Lancet Neurol. 2 (2003) 425-428
17. Morrison L.D., Smith D.D., and Kish S.J. Brain S-adenosylmethionine levels are severely decreased in Alzheimer's disease. J. Neurochem. 67 (1996) 1328-1331
18. Gomez-Isla T., Hollister R., West H., Mui S., Growdon J.H., Petersen R.C., Parisi J.E., and Hyman B.T. Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease. Ann. Neurol. 41 (1997) 17-24
19. Arriagada P.V., Growdon J.H., Hedley-Whyte E.T., and Hyman B.T. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology 42 (1992) 631-639
20. Mackay E.A., Ehrhard A., Moniatte M., Guenet C., Tardif C., Tarnus C., Sorokine O., Heintzelmann B., Nay C., Remy J.M., Higaki J., Van Dorsselaer A., Wagner J., Danzin C., and Mamont P. A possible role for cathepsins D, E, and B in the processing of beta-amyloid precursor protein in Alzheimer's disease. Eur. J. Biochem. 244 (1997) 414-425
21. Gong C.X., Shaikh S., Wang J.Z., Zaidi T., Grundke-Iqbal I., and Iqbal K. Phosphatase activity toward abnormally phosphorylated tau: decrease in Alzheimer disease brain. J. Neurochem. 65 (1995) 732-738
22. Lovestone S., and Reynolds C.H. The phosphorylation of tau: a critical stage in neurodevelopment and neurodegenerative processes. Neuroscience 78 (1997) 309-324
23. Gong C.X., Lidsky T., Wegiel J., Zuck L., Grundke-Iqbal I., and Iqbal K. Phosphorylation of microtubule-associated protein tau is regulated by protein phosphatase 2A in mammalian brain. Implications for neurofibrillary degeneration in Alzheimer's disease. J. Biol. Chem. 275 (2000) 5535-5544
24. Sontag E., Hladik C., Montgomery L., Luangpirom A., Mudrak I., Ogris E., and White III C.L. Downregulation of protein phosphatase 2A carboxyl methylation and methyltransferase may contribute to Alzheimer disease pathogenesis. J. Neuropathol. Exp. Neurol. 63 (2004) 1080-1091
25. Sontag E., Luangpirom A., Hladik C., Mudrak I., Ogris E., Speciale S., and White III C.L. Altered expression levels of the protein phosphatase 2A ABalphaC enzyme are associated with Alzheimer disease pathology. J. Neuropathol. Exp. Neurol. 63 (2004) 287-301
26. Tanimukai H., Grundke-Iqbal I., and Iqbal K. Up-regulation of inhibitors of protein phosphatase-2A in Alzheimer's disease. Am. J. Pathol. 166 (2005) 1761-1771
27. Vogelsberg-Ragaglia V., Schuck T., Trojanowski J.Q., and Lee V.M. PP2A mRNA expression is quantitatively decreased in Alzheimer's disease hippocampus. Exp. Neurol. 168 (2001) 402-412
28. Yoon S., Choi J., Huh J.W., Hwang O., and Kim D. Calpain activation in okadaic-acid-induced neurodegeneration. Neuroreport 17 (2006) 689-692
29. Bryant J.C., Westphal R.S., and Wadzinski B.E. Methylated C-terminal leucine residue of PP2A catalytic subunit is important for binding of regulatory Balpha subunit. Biochem. J. 339 Pt. 2 (1999) 241-246
30. Cohen P., and Frame S. The renaissance of GSK3. Nat. Rev. Mol. Cell Biol. 2 (2001) 769-776
31. Planel E., Yasutake K., Fujita S.C., and Ishiguro K. Inhibition of protein phosphatase 2A overrides tau protein kinase I/glycogen synthase kinase 3 beta and cyclin-dependent kinase 5 inhibition and results in tau hyperphosphorylation in the hippocampus of starved mouse. J. Biol. Chem. 276 (2001) 34298-34306
32. Gregorios J.B., Gregorios A.B., Mora J., Marcillo A., Fojaco R.M., and Green B. Morphologic alterations in rat brain following systemic and intraventricular methotrexate injection: light and electron microscopic studies. J. Neuropathol. Exp. Neurol. 48 (1989) 33-47
33. Yoon S.Y., Choi J.E., Yoon J.H., Huh J.W., and Kim D.H. BACE inhibitor reduces APP-beta-C-terminal fragment accumulation in axonal swellings of okadaic acid-induced neurodegeneration. Neurobiol. Dis. 22 (2006) 435-444
34. Sontag E., Nunbhakdi-Craig V., Sontag J.M., Diaz-Arrastia R., Ogris E., Dayal S., Lentz S.R., Arning E., and Bottiglieri T. Protein phosphatase 2A methyltransferase links homocysteine metabolism with tau and amyloid precursor protein regulation. J. Neurosci. 27 (2007) 2751-2759